Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma

NCT03207178 is registered in ClinicalTrials.gov with Shanghai Longyao Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT03207178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03207178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma
Lead sponsor
Shanghai Longyao Biotechnology Inc., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 1, 2017
Completion date
February 28, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or refractory b cell malignancy